Perfusion processes can attractive for biologics drug manufacturing; however, obstacles remain.
Xhorxhi Gjoka
Advertisement
Xhorxhi Gjoka is senior R&D engineer, Pall Life Sciences.
Articles by Xhorxhi Gjoka
Continuous processing of 100 g of monoclonal antibody in 24 hours has been demonstrated using lab-scale equipment.
Advertisement
Latest Updated Articles
- Going from Fed-Batch to Perfusion
Published: July 1st 2017 | Updated:
Platform for Integrated Continuous BioprocessingPublished: July 1st 2017 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
2
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
Selecting the Right Drug Delivery Formulations to Enhance Patient-Centric Care
5
